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Abstract
Xeroderma pigmentosum complementation group C (XPC) is an important DNA nuclear excision
repair (NER) gene that recognizes the damage caused by variety of bulky DNA adducts. We evaluated
the association of two common non-synonymous polymorphisms in XPC (Ala499Val and
Lys939Gln) with breast cancer risk in the Long Island Breast Cancer Study Project (LIBCSP), a
population-based case-control study. Genotyping of 1,067 cases and 1,110 controls was performed
by a high throughput assay with fluorescence polarization. There were no overall associations
between XPC polymorphisms and breast cancer risk. A diplotype CC-CC was significantly associated
with increased breast cancer risk compared with diplotype CA-CA (OR = 1.4, 95%CI: 1.0–1.9), but
was not significant when compared with all other diplotypes combined (OR = 1.22, 95%CI: 0.97–
1.53). No modification effects were observed for XPC genotypes by cigarette smoking status,
smoking pack years or polycyclic aromatic hydrocarbons (PAH) DNA adducts. The increase in breast
cancer risk was slightly more pronounced among women with detectable PAH-DNA adducts and
carrying the diplotype CC-CC (OR = 1.6, 95%CI: 1.1–2.2) compared to women with non detectable
PAH-DNA adducts carrying other diplotypes combined, but no statistically significant interaction
was observed (P interaction = 0.69). These data suggest that XPC have neither independent effects nor
interactions with cigarette smoking and PAH-DNA adducts for breast cancer risk. Further studies
with multiple genetic polymorphisms in NER pathway are warranted.
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1. Introduction
DNA repair plays an important role in eliminating DNA damage and maintaining genetic
integrity. Xeroderma pigmentosum complementation group C (XPC) is an important DNA
damage recognition protein involved in global genome DNA repair (GGR), a subclass of
nucleotide excision repair (NER). The XPC protein recognizes a variety of bulky DNA adducts
formed by exogenous carcinogens including those found in tobacco smoke (benzo[a]pyrene
(B[a]P) and other polycyclic aromatic hydrocarbons (PAHs)), and endogenous carcinogens,
all of which may play a role in the pathogenesis of breast cancer.1–5 It binds tightly with
another protein, HR23B, to form a stable XPC-HR23B complex. Recent studies identified the
XPC-HR23B complex as the first protein component that recognizes and binds to the damaged
sites. Interestingly, defects in XPC have been associated with many types of cancer.6–8
Transgenic mice studies also revealed predisposition to many types of cancer in XPC gene
knockout mice.9;10 These results suggest that the XPC protein plays an important role in
prevention of the DNA damage-mediated cancer occurrence. Recently, polymorphisms in
XPC have been studied for associations with squamous cell carcinoma of the head and neck
(SCCHN), lung, bladder, colorectal and breast cancer.11;12 The heterozygous XPC genotype,
Lys939Gln, but not the homozygous Gln939Gln genotype, was significantly associated with
breast cancer susceptibility in Finnish11 and Chinese populations.13 But in Caucasians,
African Americans or mixed population, no similar results were observed.12;14 Overall, the
relationship between XPC polymorphisms and breast cancer risk remains unclear.
Exposure to cigarette smoke and breast cancer risk has been investigated in numerous
epidemiological studies with controversial outcomes. A recently published meta-analysis
found that cigarette smoking had little or no independent effect on the risk of developing breast
cancer.15 This is consistent with findings in the Long Island Breast Cancer Study Project
(LIBCSP).16 However, several studies have suggested that cigarette smoking may increase
breast cancer risk among women who have smoked for a long time or before their first full-
term pregnancy.17;18 An increasing number of studies are also indicating that a positive
association between smoking and breast cancer risk may be stronger among or limited to
women with certain genotypes.19 PAH have been shown to induce mammary tumours in
laboratory-based studies.20 The major exposure sources include cigarette smoke, consumption
of PAH-containing foods (such as grilled and smoked foods), and air pollutants (from industrial
manufacturing, fires, and motor vehicle traffic). PAH-DNA adducts have been associated with
a modest increase in breast cancer risk in several epidemiologic studies,21–25 although no
apparent dose-response and substantial variation associated with sources of PAH, such as
cigarette smoking or consumption of grilled and smoked foods were observed.21;22 A previous
study indicated that workers with lower DNA repair capacity (carrying XPC-PAT+/+
genotype) had significantly increased anti-B[a]P diol epoxide-DNA adduct levels, which was
significantly related with PAH exposure.26 XPC polymorphisms (Arg492His, Ala499Val and
Lys939Gln) were shown to modify smoking-related risk of advanced colorectal adenoma, but
not bladder or breast cancer.14 Whether XPC polymorphisms modify the risk of breast cancer
by interaction with exogenous carcinogens (cigarette smoking and PAH-DNA adducts) is
unknown.
In the present study, we describe the distribution of genotype for two non-conservative variants
of XPC at codons 499 (Ala499Val) and 939 (Lys939Gln) in a large population-based case-
control study, the LIBCSP, with the aim of evaluating associations between XPC genotypes
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and haplotypes/diplotypes and breast cancer risk, and the modifying effects of cigarette
smoking and PAH-DNA adducts.
2. Materials and methods
2.1. Study design
The study methods of the LIBCSP have been described in detail previously.27 In brief, case
eligibility included adult female residents of Nassau and Suffolk counties on Long Island, NY,
who were of any age or race, who spoke English, and were newly diagnosed with in situ or
invasive breast cancer between August 1, 1996, and July 31, 1997. Potentially eligible controls
were frequency matched to the age distribution of the cases and identified through random
digit dialing for women under age 65 years, and through the Center for Medicare and Medicaid
Services (CMS) rosters for women 65 and over. Eligible controls were defined as women who
spoke English, and resided in the same Long Island counties as the cases, but with no personal
history of breast cancer. This study was conducted with approval from participating
institutional review boards, and in accordance with an assurance filed with and approved by
the United States Department of Health and Human Services. In-person interviews were
completed for 82.1% of cases (n = 1,508) and 62.8% of controls (n = 1,556). Of those who
completed the main questionnaire, 73.1% of cases (1,102) and 73.3% of controls (1,141)
donated a blood sample, and 1,067 cases and 1,110 controls with enough DNA for genotyping
were analyzed in present study. The constituent of ethnicity and age distribution were similar
between respondents who completed the main questionnaire and the subjects recruited in
present analyses (data not shown).
2.2. Laboratory methods
Genomic DNA was extracted by standard RNase/proteinase K and phenol/chloroform
treatment and genotyped by a fluorescence polarization (FP) method using a commercial
AcycloPrime™-FP SNP Detection Kit obtained from PerkinElmer Life Sciences. This
technique distinguishes the polymorphic base of a SNP by the template-directed incorporation
of a dye-labelled dideoxynucleotide onto an oligonucleotide primer that anneals just 5′ to the
polymorphic base.28 The forward and reverse primers, designed according to the human
XPC gene sequence (GeneBank accession number AH009651), were, respectively, 5′-GCC
TCT GAT CCC TCT GAT GA-3′, 5′-CAT CGC TGC ACA TTT TCT TG-3′ for Ala499Val
(NCBI rs2228000) and 5′-GCC TCA AAA CCG AGA AGA TG-3′, 5′-CTG CCT CAG TTT
GCC TTC TC-3′ for Lys939Gln (NCBI rs2228001). The sequences of TDI probes were
designed using Primer 3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3www.cgi)
as forward 5′-GTA AGG ACC CAA GCT TGC CAG-3′ for Ala499Val and reverse 5′-GGG
CGC TCA GCT CAC AGC T-3′ for Lys939Gln. The two allele-specific dye terminators used
for each of the two SNPs are C/T for Ala499Val and G/T for Lys939Gln. The assay was
validated by sequencing subjects with the three genotypes and these known samples were used
as positive controls on each plate. Finally, the fluorescence polarization was measured with a
Perkin Elmer Victor instrument. All the assays were performed with laboratory personnel
blinded to the subject’s disease status. In addition to assay specific quality control samples,
10% of samples were re-assayed after relabelling to keep laboratory staff blinded to its identity.
Concordance for re-assayed samples was 100%. Genotyping data were available for 99.5% of
breast cancer cases and 98.9% of controls with enough DNA.
The PAH-DNA adducts levels, determined by competitive ELISA, were available from the
parent study.21;22 Adduct levels were determined for 873 (79.2%) breast cancer cases and
941 (82.5%) controls who donated sufficient blood for the assay, which were 57.9%
(873/1,508) and 60.5% (941/1,556) of the eligible cases and controls, respectively.22 For the
analyses presented here, PAH-DNA adduct levels were dichotomized into a single binary
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variable: detectable (>15% inhibition in the ELISA) vs. non-detectable adducts. Full technical
details are available on request.
2.3. Questionnaire data
The main questionnaire assessed information on known and suspected risk factors for breast
cancer, including PAH exposure sources over the life course as cigarette smoking. A current
cigarette smoker was defined as smoking within the last 12 months prior to the reference date;
a former smoker was defined as a smoker who reported quitting more than 12 months prior to
the reference date.16 Light and moderate or heavy smokers were categorized by using the
50th percentile pack-year [(cigarettes per day/20) × (years smoked)] values of the controls as
the cutoff points (i.e., < 15, and 15+ pack-years). Other factors considered as potential
confounders (see below) were also assessed as part of the in-person interview.
2.4. Statistical methods
Hardy-Weinberg Equilibrium (HWE)29 was tested to compare the observed and expected
genotype frequencies among cases and controls, respectively. Chi-square tests for categorical
variables were used to assess case-control differences.30 Haplotype and diplotype frequencies
were estimated from genotype data by PHASE version 2.1.1 based on a Bayesian algorithm
and the maximum likelihood model linked with the Stochastic-EM algorithm.31;32 Haplotypes
and diplotypes were selected according to the corresponding occurring probabilities with a
higher likelihood (> 0.95 as cut-point).31–33 The most common haplotype CA was selected
as the reference in the analysis. The risk of breast cancer was estimated for each diplotype
compared to the reference (CA-CA) or all other diplotypes combined, adjusted for age at
reference. Diplotypes were treated as categorical variable and were incorporated as dummy
variables in the logistic regression models.
Unconditional logistic regression with SAS version 9.0 was used to estimate odds ratios (OR)
and corresponding 95% confidence intervals (CI).34 The potential confounding variables were
assessed by examining the percent changes (more than 10%) in the ORs of the main effects of
genotyping. Variables found not to confound the associations of interest included: age at
menarche, parity, lactation, months of lactation, age at first birth, number of miscarriages,
history of fertility problems, alcohol drinking, race, education, religion and marital status (as
previously defined).21;22;27 All models were adjusted for the frequency matching factor, age
at reference (defined as age at diagnosis for cases and age at identification for controls). Effect
modification was assessed on a multiplicative scale by calculating ORs for XPC genotypes
stratified by indicators of cigarette smoking and PAH-DNA adducts status as previously
defined.21;22;27 running separate models for each exposure category and by including
multiplicative interaction terms in the logistic regression model. The XPC genotypes were
dichotomized by assuming a dominant genetic model based on previous studies of cancer risk.
35–37 All statistical tests were two-sided, and P < 0.05 as the criteria of statistical significance.
3. Results
The frequencies of the XPC polymorphisms (Ala499Val and Lys939Gln) did not deviate
significantly from the Hardy-Weinberg equilibrium (P values were 0.45 and 0.18,
respectively). For the codon 499 locus, the frequencies of the CC, CT, and TT genotypes were
57.2%, 37.7%, and 5.1%, respectively, among the control subjects (Table 1). The
corresponding frequencies among the cases were 57.9%, 36.3%, and 5.8%, respectively. The
frequencies of the AA, AC, and CC genotypes for the codon 939 locus were 33.2%, 51.2%,
and 15.6 % among controls, and 32.5%, 49.1%, and 18.5% among cases. Overall, the
distribution of XPC genotypes did not vary significantly between cases and controls when
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separately analyzing the two variant alleles, either among pre- or post- menopausal women
(data not shown).
Haplotypes CC and TA did not have any relationships with breast cancer risk compared with
the reference haplotype, CA (Table 1). Common diplotypes (CC-TA, CC-CA and CA-TA)
were not associated with statistically significant increased breast cancer risk, except diplotype
(CC-CC) that displaying a significantly increased breast cancer risk, when compared with the
diplotype CA-CA (OR = 1.4, 95%CI: 1.0–1.9), but not when compared with all other diplotypes
combined as the reference (OR = 1.22, 95%CI: 0.97–1.53, P = 0.09).
Overall, there was no modification effects observed between XPC genotypes and breast cancer
risk by cigarette smoking status, neither in former nor in current smokers (Table 2). In the
multivariate analysis with adjustment for age at reference, we observed increased ORs in
subgroups with <15 or 15+ pack years smoking and carrying either XPC 939 or XPC 499 variant
alleles compared with never smokers carrying wild-type genotype, but there was no significant
heterogeneity across these cells. No significant associations were observed between XPC
genotypes and breast cancer risk by passive smoking status (data not shown).
Statistically significant increased breast cancer risks were found among women with detectable
PAH-DNA adducts, in carriers of the XPC 499CC genotype and XPC 939AC/CC or AA
genotypes (Table 2). No significant multiplicative interactions were observed between any
XPC variant allele and detectable PAH-DNA adducts. There was no evidence of a dose-
response relationship between XPC genotypes and higher level of PAH-DNA adducts for breast
cancer risk, although some subgroups showed significant differences (Table 2).
Based on the potential relationship between the diplotype CC-CC and breast cancer risk
observed above, we further analyzed the potential effect modifications of cigarette smoking
and PAH-DNA adducts (Table 3). Overall we found no statistically significant modifications
for XPC CC-CC diplotype either by cigarette smoking status or smoking pack-years. However,
a statistically significant increased breast cancer risk was observed in the subgroup carrying
the CC-CC diplotype and exposed to moderate or heavy smoking (OR = 3.7, 95%CI: 1.8–7.6)
compared to never smokers carrying other diplotypes combined, but with a small sample size.
The increase in breast cancer risk was slightly more pronounced among women with detectable
PAH-DNA adducts and carrying diplotype CC-CC (OR = 1.6, 95%CI: 1.1–2.2) compared to
women with non detectable PAH-DNA adducts carrying all other diplotypes combined, but
no statistically significant interaction was observed (P interaction = 0.69). There was no evidence
of a modifying effect for the CC-CC diplotype and breast cancer risk by higher level of PAH-
DNA adducts.
4. Discussion
Although some significant results were observed in several subgroups, the present study does
not support the hypothesis that genotypes or haplotype/diplotype of XPC Ala499Val and
Lys939Gln have an independent etiological role in breast cancer nor do they interact with
cigarette smoking or PHA-DNA adducts. This is consistent with a recent epidemiological study
indicating no relationship between XPC polymorphisms and breast cancer risk in Caucasians,
African Americans or mixed population,12;14 but is in conflict with reports in Finnish11 and
Chinese13 populations. Of course, the different ethnic groups included in various studies may
partly account for the conflicting results on whether or not XPC polymorphisms have
independent effects and interaction with cigarette smoking for breast cancer risk, but other
explanations should also be considered.
Methodological issues of inadequate study design should be considered, such as nonrandom
sampling, limited sample size, lack of statistical power and precision in subgroups.19 Most
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previous studies with positive findings may have been underpowered, which may contribute
to spurious findings. According to one estimate, approximately 68% of stratum-specific
analyses had less than 80% power to detect an OR of 2.0 between genotypes and breast cancer
risk modified by cigarette smoking status.19 Thus, earlier findings of a positive association
between XPC polymorphisms and cancer risk in select subgroups with small sample sizes are
likely false positives due to chance. In the present study, we estimated the power of detecting
an OR of 1.5 at significance level of 0.05 based on our sample size and the minor allele
frequency. The power for XPC codon 499 and 939 variant alleles were, respectively, 97% and
99%. The lack of an association between XPC polymorphisms and breast cancer risk in the
current study is thus not due to insufficient statistical power.
Another explanation for the inconsistent results across studies may be related to the opposing
effects of smoking on breast cancer risk.18;38 Oestrogen is a known risk factor for breast
cancer. The carcinogenic effects of DNA-damaging agents such as B[a]P and other aromatic
hydrocarbons in cigarette smoke may have an antioestrogenic effect by acting as non-steroidal
oestrogens39 or activate the oestrogen receptor α.40 A recent study41 that found a significant
inverse trend for cumulative pack-years of cigarette smoking and breast cancer risk among
parous women supports our observations. In this recent report, cigarette smoking was found
to have a harmful effect among women who began smoking before the birth of their first child,
but among women who began smoking after the first live birth, the risk for breast cancer was
reduced. These results suggest that the risk of breast cancer from cigarette smoking may vary
with the timing of the exposure over the lifecourse.41 Although these observations have not
been consistently reported across investigations,16;42–44 it is possible that the lack of
consideration of a possible interaction with oestrogen exposure, or for the effect of cigarette
smoking during different periods, may mask or dilute real associations.
A third possible explanation is that most previous studies did not consider the complex gene-
environment interactions. As part of the parent LIBCSP study,21;22 participants were
characterized in terms of PAH-DNA adducts, enhancing the precision of defining individual
PAH body burden. Most previous studies lack an exposure biomarker, possibly biasing
(overestimating) the independent or interaction effects of XPC polymorphisms and cigarette
smoking for breast cancer risk due to the inaccurate categorization of cigarette smoke exposure.
Finally, only two polymorphisms in XPC gene involved in recognition of DNA damage were
explored in present study. There were more than thirty other genes involved in the NER
pathway were not considered. Crew and colleagues observed that a combined effect of
polymorphisms in NER genes revealed a modest, statistically significant positive association
between number of putative high-risk alleles and breast cancer risk in LIBCSP.45 A previous
study conducted in the same population observed that a polymorphism in XPD codon 751, also
functioning in the NER pathway, statistically significantly increased breast cancer risk from
PAH-DNA adducts and cigarette smoking exposure.46 Moreover, XPC has a much broader
role in affecting other DNA repair pathways.47 But we did not observe any gene-gene
interactions between the two XPC polymorphisms and XPD codon 751 in the present study
(data not shown). These results suggest that the two XPC polymorphisms may not
independently play a critical role in breast tumourigenesis, or at least, have a less important
role than XPD polymorphisms. Even if the XPC polymorphisms affect breast cancer risk, it
may not be through interaction with exposure to cigarette smoking or PAH-DNA adducts.
Although increased breast cancer risk was observed in subgroups carrying the CC-CC
diplotype and exposed to moderate/heavy smoking or detectable PAH-DNA adducts, the lack
of a priori functional data as well as the limitation of haplotype/diplotype imputation limits
the interpretation of the data.48
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The relatively large sample size, population-based study design, and both genotyping and
exposure biomarker (PAH-DNA adducts) available, are the strengths of this study. Recall bias
is one limitation that is common to case-control studies; but because neither cases nor controls
were aware of their genotype and the exposure biomarker at the time of the interview, the
accuracy of the response is not likely to be related to genotype or exposure status. Although
the exposure information on cigarette smoking may be differentially recalled by cases and
controls due to the cases’ cancer diagnosis, this misclassification would not differ by genotype
and PAH-DNA adducts status. Although our results were obtained from a mixed population,
most of them (>93%) were Caucasians. The potential influence of ethnic heterogeneity might
not bias the conclusion. Extensive information collected in the study for evaluating
confounding factors and effect modifiers allows us to control for confounding in data analysis.
The OR for XPC polymorphism and breast cancer risk changed less than 10% when considering
potential confounding factors individually or in multivariate models indicating that
confounding did not dramatically affect the results. Age at reference included in logistic
models, minimized any possible residual confounding effect of age.
In conclusion, we did not find any independent main effects of XPC polymorphisms for breast
cancer risk or interaction with cigarette smoking/PAH-DNA adducts, although several
significant differences were observed for subgroups with XPC variant alleles or diplotypes and
specific carcinogenic exposures. There is evidence suggesting that the two XPC
polymorphisms are linked with a functional SNP in 3′ of intron 11 splice acceptor site and may
decrease DNA repair activity of single strand breaks.49;50 However, the biological effects of
the two SNPs under conditions of carcinogenic exposure remain to be determined.
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Table 1
XPC genotype or haplotype/diplotype cases, n (%) controls, n (%) OR(95%CI)*
Ala499Val genotype
 CC 614 (57.9) 632 (57.2) 1.0 (reference)
 CT 385 (36.3) 417 (37.7) 0.9 (0.8–1.1)
 TT 62 (5.8) 56 (5.1) 1.1 (0.8–1.6)
 CT/TT 447 (42.1) 473 (42.8) 1.0 (0.8–1.1)
Lys939Gln genotype
 AA 344 (32.5) 366 (33.2) 1.0 (reference)
 AC 520 (49.1) 565 (51.2) 1.0 (0.8–1.2)
 CC 196 (18.5) 172 (15.6) 1.2 (0.9–1.5)
 AC/CC 716 (67.6) 737 (66.8) 1.0 (0.9–1.2)
Haplotypes†
 CA 706 (33.3)‡ 769 (34.9)‡ 1.0 (reference)
 CC 905 (42.7) 908 (41.2) 1.1 (0.9–1.2)
 TA 502 (23.7) 528 (23.9) 1.0 (0.9–1.2)
Diplotypes (haplotype pairs)
 CA-CA 117 (11.0) 142 (12.9) 1.0 (reference)
 CC-TA 215 (20.3) 249 (22.6) 1.0 (0.8–1.4)
 CC-CA 300 (28.3) 316 (28.6) 1.2 (0.9–1.6)
 CC-CC 196 (18.5) 172 (15.6) 1.4 (1.0–1.9) |§
 CA-TA 170 (16.0) 168 (15.2) 1.2 (0.9–1.7)
 Other haplotype pairs 62 (5.9) 56 (5.1) 1.3 (0.9–2.1)
 Total 1,060 (100.0) 1,103 (100.0)
*
Adjusted for age at reference.
†




OR = 1.22 (95%CI: 0.97–1.53) when all other haplotype pairs combined as reference, P = 0.09.
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Table 3
Exposure status XPC diplotypes
All other diplotypes combined CC-CC diplotype
Case/control OR (95%CI)* Case/control OR (95%CI)*
Never smokers 383/418 1.0 (reference) 103/80 1.4 (1.0–1.9)
Former smokers† 307/333 1.0 (0.8–1.2) 63/63 1.1 (0.7–1.6)
Current smokers† 174/179 1.1 (0.9–1.5) 30/28 1.2 (0.7–2.1)
Never smokers 383/419 1.0 (reference) 103/80 1.4 (1.0–1.9)
< 15 pack-years smokers † 121/91 1.5 (1.1–2.0) 20/16 1.4 (0.7–2.7)
15+ pack-years smokers † 138/100 1.5 (1.1–2.0) 34/10 3.7 (1.8–7.6)
PAH-DNA adducts
Non detectable 185/244 1.0 (reference) 38/46 1.1 (0.7–1.8)
Detectable 521/548 1.3 (1.0–1.6) 118/98 1.6 (1.1–2.2)‡
Non detectable 185/244 1.0 (reference) 38/46 1.1 (0.7–1.8)
Detectable (below median) 262/269 1.3 (1.0–1.7) 67/53 1.7 (1.1–2.5)
Detectable (median and above) 259/279 1.2 (0.9–1.6) 51/45 1.5 (0.9–2.3)
*
adjusted for age at reference.
†
total number of smokers <15 pack-years and 15+ pack-years less than that of former and current smokers are due to missing data for cigarettes per day
or smoked years.
‡
P interaction = 0.69.
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